Glaukos Corporation $GKOS Shares Purchased by Holocene Advisors LP

Holocene Advisors LP grew its position in shares of Glaukos Corporation (NYSE:GKOS) by 40.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,045,886 shares of the medical instruments supplier’s stock after buying an additional 299,118 shares during the period. Holocene Advisors LP owned about 1.82% of Glaukos worth $108,030,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Park Place Capital Corp raised its position in shares of Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 162 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 633 shares during the period. Parkside Financial Bank & Trust lifted its position in shares of Glaukos by 909.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock worth $129,000 after buying an additional 1,128 shares during the last quarter. Bayforest Capital Ltd acquired a new position in shares of Glaukos in the 1st quarter valued at about $141,000. Finally, M&T Bank Corp acquired a new position in shares of Glaukos in the 2nd quarter valued at about $203,000. 99.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on GKOS. Wells Fargo & Company increased their price objective on shares of Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Truist Financial set a $120.00 price target on Glaukos in a research report on Thursday, October 30th. Citigroup boosted their price objective on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC upped their price objective on Glaukos from $117.00 to $125.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Zacks Research cut Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.62.

Glaukos Stock Performance

Shares of GKOS stock opened at $109.00 on Friday. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The firm has a market capitalization of $6.26 billion, a price-to-earnings ratio of -70.78 and a beta of 0.69. The business has a 50 day simple moving average of $91.77 and a 200 day simple moving average of $92.79.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. During the same quarter in the previous year, the firm posted ($0.28) EPS. The firm’s quarterly revenue was up 38.1% on a year-over-year basis. On average, equities research analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Insider Activity at Glaukos

In other news, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the completion of the sale, the director directly owned 34,905 shares of the company’s stock, valued at approximately $3,744,259.35. This represents a 12.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Alex R. Thurman sold 315 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total transaction of $33,075.00. Following the transaction, the chief financial officer owned 50,488 shares in the company, valued at $5,301,240. This represents a 0.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 24,655 shares of company stock worth $2,310,025 in the last 90 days. Corporate insiders own 5.80% of the company’s stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.